{"organizations": [], "uuid": "e6e77399ca0bd6784f69b0005fecea7900270634", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nuuvera-enters-into-definitive-agr/brief-nuuvera-enters-into-definitive-agreement-to-acquire-remaining-interest-in-ara-avanti-rx-analytics-idUSASB0C717", "country": "US", "domain_rank": 408, "title": "BRIEF-Nuuvera Enters Into Definitive Agreement To Acquire Remaining Interest In ARA-Avanti Rx Analytics", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T16:10:00.000+02:00", "replies_count": 0, "uuid": "e6e77399ca0bd6784f69b0005fecea7900270634"}, "author": "", "url": "https://www.reuters.com/article/brief-nuuvera-enters-into-definitive-agr/brief-nuuvera-enters-into-definitive-agreement-to-acquire-remaining-interest-in-ara-avanti-rx-analytics-idUSASB0C717", "ord_in_thread": 0, "title": "BRIEF-Nuuvera Enters Into Definitive Agreement To Acquire Remaining Interest In ARA-Avanti Rx Analytics", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "nuuvera inc", "sentiment": "none"}, {"name": "ara-avanti rx analytics reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nuuvera inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 22, 2018 / 2:11 PM / in 9 minutes BRIEF-Nuuvera Enters Into Definitive Agreement To Acquire Remaining Interest In ARA-Avanti Rx Analytics Reuters Staff Feb 22 (Reuters) - Nuuvera Inc: * NUUVERA ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REMAINING INTEREST IN ARA-AVANTI RX ANALYTICS INC. * NUUVERA ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REMAINING INTEREST IN ARA-AVANTI RX ANALYTICS INC. * NUUVERA INC - ‍TOTAL CONSIDERATION FOR AVANTI TRANSACTION IS EXPECTED TO BE APPROXIMATELY $43 MILLION​ * NUUVERA INC - ‍PURSUANT TO AGREEMENT, PURCHASE PRICE FOR 49% INTEREST OF AVANTI IS $35 MILLION​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T16:10:00.000+02:00", "crawled": "2018-02-22T16:22:34.003+02:00", "highlightTitle": ""}